Article Listing - Generics
Shire prevails in US Lialda patent dispute with Watson
10 May 2013
Ireland-headquartered drugmaker Shire's (LSE: SHP) subsidiary Shire Development has prevailed in its US litigation against three companies (now trading as Actavis: NYSE: ACT) in connection with their Abbreviated New Drug Application for a generic version of Shire's Lialda (mesalamine) delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.
ScinoPharm Taiwan and Coland in strategic alliance for generic oncology injectables
10 May 2013
ScinoPharm Taiwan (TSE: 1789.TW) and Coland Holdings (TSE: 4144.TW) have formed a strategic alliance to develop a series of generic oncological drugs for Mainland China. Several active pharmaceutical ingredients (APIs) have been initially selected for development and future sales as injectable formulation products from the list of ScinoPharm-developed APIs. This will allow the companies to compete within the anti-cancer drug market in China and tap into this large and growing business potential.
Total real per capita spending on medicines in the USA fell 3.5% in 2012
9 May 2013
Total spending on US medicines fell 3.5 percent on a real per capita basis in 2012 and the use of health care services overall declined for the second consecutive year, according to a new study released today by the IMS Institute for Healthcare Informatics.
Canada strengthens drug safety with GMP now to apply to all APIs
9 May 2013
Canada's Health Minister Leona Aglukkaq this week announced that Canada's Food and Drug Regulations have been amended to extend the requirements for Good Manufacturing Practices (GMP) to active pharmaceutical ingredients (APIs) used in medicines. These amendments will come into force in the fall of this year.
Florida joins growing list of US states blocking some Biosimilars Bills provisions
8 May 2013
Last Friday, the US state of Florida joined several states, most recently Indiana, in refusing to enact legislation that would create barriers between patients and newer, lower-cost versions of biologic medicines known as biosimilars. The Florida legislature voted to approve a bill on biosimilars that follows current substitution practices for prescription medicines, rejecting efforts by US biotech majors Amgen and Genentech (part of Roche) to limit future access to these therapies once they reach the market.
Global biosimilar drug revenues will reach $2,445 million in 2013, says Visiongain
8 May 2013
The world market for biosimilar drugs will be worth $2,445 million in 2013, growing by more than 20% from 2012, according to a new report from Visiongain. In 2013 it will account for around 2% of the overall biological drugs market, and the study forecasts rapid growth to 2023 for the global biosimilars market.
Ranbaxy 1st-qtr 2013 earnings plunge 90% as sales fall 34%
8 May 2013
India's largest pharma company Ranbaxy Laboratories (BSE: 500359), which is majority owned by Japan's Daiichi Sankyo, has posted first quarter 2013 financial results, showing the net income plunged 90% to 1.26 billion rupees ($23.4 million), while sales fell 34.2% to 24.40 billion rupees compared with the 2012 first quarter, when the company benefited from sales exclusivity in the USA for a generic version for a generic version of Pfizer's all-time blockbuster Lipitor (atorvastatin).
Australia to review way chemotherapy is funded
7 May 2013
Australia's Minister for Health Tanya Plibersek has announced a major review into the way chemotherapy is funded and provided as a way of ensuring the nation's cancer patients have continued access to quality, affordable treatment.
US FDA warns pregnant women to not use valproate migraine prevention medicines
7 May 2013
The US Food and Drug Administration is alerting health care providers and patients that medications including and related to valproate sodium, an epilepsy treatment, can cause decreased IQ scores in children whose mothers took the drugs during pregnancy.
Sagent Pharma to buy remaining 50% stake in Chinese JV for $25 million
6 May 2013
US specialty pharmaceutical company Sagent Pharmaceuticals (Nasdaq: SGNT) has entered into an agreement to acquire the 50% interest of its joint venture partner, Chengdu Kanghong Pharmaceuticals (Group), formerly Chengdu Kanghong Technology (Group) in the Kanghong Sagent (Chengdu) Pharmaceutical (KSCP) joint venture, for $25 million, payable in installments through September 2015. On completion of the acquisition, which is expected in the next several months, KSCP will become a wholly-owned subsidiary of Sagent.
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
